PTGS2 and cutaneous melanoma: In human cutaneous melanomas, COX2 has been proposed as a diagnostic IHC marker to differentiate early lesions from benign melanocytomas [111], and in canine cutaneous and oral melanomas, COX2 may be an independent predictive marker for overall survival [112].